325 related articles for article (PubMed ID: 27920181)
1. Chikungunya Virus Vaccines: Viral Vector-Based Approaches.
Ramsauer K; Tangy F
J Infect Dis; 2016 Dec; 214(suppl 5):S500-S505. PubMed ID: 27920181
[TBL] [Abstract][Full Text] [Related]
2. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.
García-Arriaza J; Cepeda V; Hallengärd D; Sorzano CÓ; Kümmerer BM; Liljeström P; Esteban M
J Virol; 2014 Mar; 88(6):3527-47. PubMed ID: 24403588
[TBL] [Abstract][Full Text] [Related]
3. A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice.
Weger-Lucarelli J; Chu H; Aliota MT; Partidos CD; Osorio JE
PLoS Negl Trop Dis; 2014 Jul; 8(7):e2970. PubMed ID: 25058320
[TBL] [Abstract][Full Text] [Related]
4. Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.
DeZure AD; Berkowitz NM; Graham BS; Ledgerwood JE
J Infect Dis; 2016 Dec; 214(suppl 5):S497-S499. PubMed ID: 27920180
[TBL] [Abstract][Full Text] [Related]
5. Measles-vectored vaccine approaches against viral infections: a focus on Chikungunya.
Gerke C; Frantz PN; Ramsauer K; Tangy F
Expert Rev Vaccines; 2019 Apr; 18(4):393-403. PubMed ID: 30601074
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.
Reisinger EC; Tschismarov R; Beubler E; Wiedermann U; Firbas C; Loebermann M; Pfeiffer A; Muellner M; Tauber E; Ramsauer K
Lancet; 2019 Dec; 392(10165):2718-2727. PubMed ID: 30409443
[TBL] [Abstract][Full Text] [Related]
7. Development of Vaccines for Chikungunya Fever.
Erasmus JH; Rossi SL; Weaver SC
J Infect Dis; 2016 Dec; 214(suppl 5):S488-S496. PubMed ID: 27920179
[TBL] [Abstract][Full Text] [Related]
8. Construction and Immunogenicity of Recombinant Vaccinia Virus Vaccine Against Japanese Encephalitis and Chikungunya Viruses Infection in Mice.
Zhang Y; Han JC; Jing J; Liu H; Zhang H; Li ZH; Jin NY; Lu HJ
Vector Borne Zoonotic Dis; 2020 Oct; 20(10):788-796. PubMed ID: 32584657
[TBL] [Abstract][Full Text] [Related]
9. Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus.
Roques P; Ljungberg K; Kümmerer BM; Gosse L; Dereuddre-Bosquet N; Tchitchek N; Hallengärd D; García-Arriaza J; Meinke A; Esteban M; Merits A; Le Grand R; Liljeström P
JCI Insight; 2017 Mar; 2(6):e83527. PubMed ID: 28352649
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.
Ramsauer K; Schwameis M; Firbas C; Müllner M; Putnak RJ; Thomas SJ; Desprès P; Tauber E; Jilma B; Tangy F
Lancet Infect Dis; 2015 May; 15(5):519-27. PubMed ID: 25739878
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate CHIKV Vaccine.
Henss L; Yue C; Von Rhein C; Tschismarov R; Lewis-Ximenez LL; Dölle A; Baylis SA; Schnierle BS
J Infect Dis; 2020 Apr; 221(10):1713-1723. PubMed ID: 31828322
[TBL] [Abstract][Full Text] [Related]
12. Adenoviral-Vectored Mayaro and Chikungunya Virus Vaccine Candidates Afford Partial Cross-Protection From Lethal Challenge in A129 Mouse Model.
Campos RK; Preciado-Llanes L; Azar SR; Kim YC; Brandon O; López-Camacho C; Reyes-Sandoval A; Rossi SL
Front Immunol; 2020; 11():591885. PubMed ID: 33224148
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus.
López-Camacho C; Kim YC; Blight J; Lazaro Moreli M; Montoya-Diaz E; Huiskonen JT; Kümmerer BM; Reyes-Sandoval A
Viruses; 2019 Apr; 11(4):. PubMed ID: 30987160
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and Efficacy of a Measles Virus-Vectored Chikungunya Vaccine in Nonhuman Primates.
Rossi SL; Comer JE; Wang E; Azar SR; Lawrence WS; Plante JA; Ramsauer K; Schrauf S; Weaver SC
J Infect Dis; 2019 Jul; 220(5):735-742. PubMed ID: 31053842
[TBL] [Abstract][Full Text] [Related]
15. A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections.
Chattopadhyay A; Aguilar PV; Bopp NE; Yarovinsky TO; Weaver SC; Rose JK
Vaccine; 2018 Jun; 36(27):3894-3900. PubMed ID: 29807712
[TBL] [Abstract][Full Text] [Related]
16. Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology.
Eldi P; Cooper TH; Liu L; Prow NA; Diener KR; Howley PM; Suhrbier A; Hayball JD
Mol Ther; 2017 Oct; 25(10):2332-2344. PubMed ID: 28720468
[TBL] [Abstract][Full Text] [Related]
17. A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.
Chattopadhyay A; Wang E; Seymour R; Weaver SC; Rose JK
J Virol; 2013 Jan; 87(1):395-402. PubMed ID: 23077320
[TBL] [Abstract][Full Text] [Related]
18. Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine.
Zhang YN; Deng CL; Li JQ; Li N; Zhang QY; Ye HQ; Yuan ZM; Zhang B
J Virol; 2019 Aug; 93(15):. PubMed ID: 31092567
[TBL] [Abstract][Full Text] [Related]
19. Chikungunya Virus Vaccine Candidates with Decreased Mutational Robustness Are Attenuated
Carrau L; Rezelj VV; Noval MG; Levi LI; Megrian D; Blanc H; Weger-Lucarelli J; Moratorio G; Stapleford KA; Vignuzzi M
J Virol; 2019 Sep; 93(18):. PubMed ID: 31270226
[TBL] [Abstract][Full Text] [Related]
20. Optimized production and immunogenicity of an insect virus-based chikungunya virus candidate vaccine in cell culture and animal models.
Adam A; Luo H; Osman SR; Wang B; Roundy CM; Auguste AJ; Plante KS; Peng BH; Thangamani S; Frolova EI; Frolov I; Weaver SC; Wang T
Emerg Microbes Infect; 2021 Dec; 10(1):305-316. PubMed ID: 33539255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
